Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Watch our mini-video series from #ILC2022
We tried something new, check it out: Short video interviews by curious patient representatives from the European Liver Patients’ Association (ELPA) who asked Prof. Dr. Jonel Trebicka, our scientific coordinator, questions about the MICROB-PREDICT, its clinical trial, and its impact. The interviews were conducted during the International Liver Congress (ILC) in London, United Kingdom, in June 2022.More news
14th International Meeting on Therapy in Liver Diseases
From 21-23 September 2022, the 14th edition of the International Meeting on Therapy in Liver Diseases organised by the Liver Unit at Hospital Clinic of Barcelona will take place. The aim of the meeting is to highlight and discuss the latest advances in Clinical Hepatology to be applied in every day clinical practice. On Thursday, 22nd September at 5.45 p.m., MICROB-PREDICT Coordinator, Jonel Trebicka, will give a talk on “The microbiota in cirrhosis: under- or overrated”. Find more information here.More events